Paraneoplastic vesiculobullous dermatomyositis with synchronic prostate and tongue tumors: Case report

Revista Brasileira de Reumatologia

Volumn 51, Issue 4, 2011, Pages 394-400

  Caratta, Paula Renaux ^a   Mafort, Thiago ^a,b   Pamplona, Monique ^a   Schau, Bruno ^a,b   Estrella, Rogerio R ^a,b   Ramos, Ricardo Carneiro ^a,b  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b Hospital Antônio Pedro of the UFF   (Brazil)

Author keywords

Dermatomyositis; Paraneoplastic syndromes; Prostate neoplasias; Tongue neoplasias

Indexed keywords

AMITRIPTYLINE; ANTIANDROGEN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; CHLORTALIDONE; ENALAPRIL; GLUCOCORTICOID; METFORMIN; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TRAMADOL;

AGED; ARTICLE; ASTHENIA; CANCER RADIOTHERAPY; CANCER REGRESSION; CASE REPORT; CERVICAL LYMPH NODE; CLINICAL EXAMINATION; CLINICAL FEATURE; COMORBIDITY; DERMATOMYOSITIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; ECHOGRAPHY; ERYTHEMA; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LARYNGOSCOPY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHADENOPATHY; MALE; MUSCLE WEAKNESS; MYOPATHY; PARANEOPLASTIC VESICOBULLOUS DERMATOMYOSITIS; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; RECURRENT DISEASE; SKIN BIOPSY; SKIN PRURITUS; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME; TUMOR BIOPSY; URINE INCONTINENCE; VESICULAR RASH; WEIGHT REDUCTION;

AGED; DERMATOMYOSITIS; HUMANS; MALE; NEOPLASMS, MULTIPLE PRIMARY; PARANEOPLASTIC SYNDROMES; PROSTATIC NEOPLASMS; SKIN DISEASES, VESICULOBULLOUS; TONGUE NEOPLASMS;

EID: 79960613086     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Curr Mol Med 2002; 2(6):571-7.
2. Little DG, Peat RA, Mcevoy A, Williams PR, Smith EJ, Baldock PA. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J Bone Miner Res 2003; 18(11):2016-22.
3. Astrand J, Aspenberg P. Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats. BMC Musculoskelet Disord 2002; 7(3):19.
4. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004; 9 (Suppl 4):28-37.
5. Diego R, D'Orto O, Pagani D, Agazzi A, Marzano U, Derada Troletti G et al. Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103(3):e1-e5.
6. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19(2):558-67.
7. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19(1):80-100.
8. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61(9):1115-7.
9. Hohnecker JA. Novartis "Dear Doctor" precautions added to label of Aredia and Zometa. September 24, 2004. Citado por Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update. J Oral Maxillofac Surg 2009; 67(5 Suppl):2-12.
10. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009; 67(5 Suppl):2-12.
11. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D et al. Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22(10):1479-91.
12. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S et al. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 2010; 28:365-83.
13. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 2008; 66(4):625-31.
14. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff S. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62:527-34.
15. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis\osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005; 63:1567-75.
16. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate- associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65:415-23.
17. Ault A. Jaw necrosis affects 1 in 1,700 on oral bisphosphonates. Internal Medicine News 2008; 41(Aug 1):23.
18. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23(34):8580-7.
19. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23(6):826-36.
20. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006; 134(6):620-3.
21. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23(34):8580-7.
22. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20(1):117-20.
23. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumor patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009; 20(1):137-45.